The estimated Net Worth of Charles Alpuche is at least 22 百万$ dollars as of 14 March 2023. Mr. Alpuche owns over 12,663 units of Insulet stock worth over 13,264,589$ and over the last 9 years he sold PODD stock worth over 5,380,247$. In addition, he makes 3,347,240$ as Chief Operating Officer、 Executive Vice President at Insulet.
Charles has made over 13 trades of the Insulet stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 12,663 units of PODD stock worth 399,898$ on 14 March 2023.
The largest trade he's ever made was exercising 23,401 units of Insulet stock on 13 March 2023 worth over 730,345$. On average, Charles trades about 1,946 units every 54 days since 2016. As of 14 March 2023 he still owns at least 58,247 units of Insulet stock.
You can see the complete history of Mr. Alpuche stock trades at the bottom of the page.
Charles Alpuche serves as Chief Operating Officer, Executive Vice President of the Company. Mr. Alpuche has served as our Executive Vice President and Chief Operating Officer since February 2019. From February 2018 to February 2019, Mr. Alpuche served as our Executive Vice President and Chief Operations Officer. From February 2017 to February 2018, Mr. Alpuche served as our Executive Vice President, Global Manufacturing and Operations, and from February 2016 to February 2017, he served as our Senior Vice President, Global Manufacturing and Operations. From 2012 to February 2016, Mr. Alpuche served as an independent consultant for both domestic and international companies in the food, beverage and chemical industries. Previously, Mr. Alpuche spent thirty years at PepsiCo in leadership roles of increasing responsibility overseeing domestic and international plant operations. Earlier in his career at PepsiCo, he held a number of management roles in plant operations, product management and quality control. Most recently, he served as PepsiCo’s Senior Vice President of North America Beverages, and before that he held the position of Vice President and General Manager, Concentrate Operations, Asia and Americas. Mr. Alpuche holds a Bachelor of Science in Business Administration from Delaware Valley College and obtained an Executive Master of Science in Organizational Management from the University of Pennsylvania.
As the Chief Operating Officer、 Executive Vice President of Insulet, the total compensation of Charles Alpuche at Insulet is 3,347,240$. There are 2 executives at Insulet getting paid more, with Shacey Petrovic having the highest compensation of 5,883,980$.
Charles Alpuche is 60, he's been the Chief Operating Officer、 Executive Vice President of Insulet since 2018. There are 5 older and 15 younger executives at Insulet. The oldest executive at Insulet Corporation is John Fallon, 72, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O THE L.S. STARRETT COMPANY, 121 CRESCENT STREET, ATHOL, MA, 01331.
Over the last 18 years, insiders at Insulet have traded over 64,849,299$ worth of Insulet stock and bought 175,262 units worth 7,280,516$ . The most active insiders traders include Jonathan Silverstein、Elizabeth H Weatherman、Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of 2,473,148$. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth 1,129,200$.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: